RESEARCH
EXPERIENCE
- The efficacy and safety of
Depakote in subjects with migraines
- An open label study for the safety
of long term Tiagabine HCl in subjects with epilepsy
- A randomized, double blind,
placebo controlled, comparision of the study drug to placebo in subjects
with painful diabetic polyneuropathy
- A randomized,
placebo-controlled, double-blind, 16 week study of the safety and
tolerability of the study medication in patients with mild to moderate
Alzheiner’s disease
- A placebo-controlled, dose
ranging safety and tolerability pilot study of remacemide hydrochloride in
subjects with probable Alzheimer’s disease
- A double blind randomized,
placebo controlled study to access the efficacy and tolerability of
Tizanidine tablets for inpatients suffering from spasticity due to
Multiple Sclerosis
- An open lable long tern study to
evaluate the safety of Tizandine tablets in patients sufferinf from
spasticity due to Multiple Sclerosis
- A double-blind, placebo
controlled study of Alzene in Alzehimer’s patients with mild to moderatly
severe cognative decline
- Delay in nursing home placement
of Alzheimer’s diesase patietns treated with the Aricept Clinical Program
- Multicenter, open label study of
the safety and tolerability of metrifonate in patients with probable
Alzehimer’s disease
- Double-blind, placebo-controlled
trial to evelauate the safety and efficacy of fixed-dose metifonate
tablets in patients with probable Alzehimer’s disease
- Trial to evaluate the safety and
efficacy of a fixed-dose metrifonate tablet comparing a loading dose phase
and no loading dose phase vs placebo in patients with probable Alzheimer’s
disease
- Open-label study of the safety
and tolerability of metrifonate in patietns with probable Alzheimer’s
diesease.
- Long-term treatment with
metrifonate for patients with probable Alzhemier’s diesase.
- A double-blind, active
controlled trial to evaluate the safety of switching patients with mild to
moderate Alzehimer’s disease from Donepezil to Metrifonate
- Study of the efficacy, safety
and tolerability 30mg anf 90mg Busprione hydrochloride extended relaese
compared to placebo in patients with generalized Anxeity Disorder
- Efficacy, safety and
tolerabiltiy of up to 90mg Busprine hydochloride Extended Release in
patients with Generalized Anxeity Disorder
- Efficacy and safety of 6, 12, 24 and 36 mg tid po and 36mg bid po talsaclidine (free base)
for 12 weeks in patients with mild to moderate dementia of Alzheimer’s
type
- Long-tern safety and tolerability of oral
administration of Talsaclidine 24mg TID in
patients with mild to moderate dementia of the Alzheimer type
- Open pilot study of study medication to identify
a safe and effective dose range for the treatment of symptoms of Mild
Dementia of the Alzheimer type
- A placebo controlled study of the medication in
Alzheimer’s type Demented patients
- An open multi-center trial of Nefazodone
on the treatment of patients with mood disorders
- Trial of Nefazodone vs placebo in the treatment of elderly depressed
outpatients
- Oxiracentam in the treatment of primary degenerative
dementia of mild to moderate severity, low dose schedule
- Oxiracentam in the treatment of primary degenerative dementia
of mild to moderate severity, high dose schedule
- Oxiracentam in the treatment of multiple infarct dementia
mild to moderate severity, low dose schedule
- Evaluation of the safety and efficacy of the
study drug in patients with Alzheimer’s disease
- Preliminary study to determine the efficacy and
safety of donepezil hydrochloride in patients
with persistent mild to moderate memory impairments resulting from a
single closed head injury
- Evaluation of the study and efficacy of the study
drug in patients with Alzheimer’s disease
- A 24 week placebo controlled evaluation of the
efficacy and safety of Donepezil Hydrochloride
in patients with dementia associated with cerebrovascular
disease
- A 30 week, open-label evaluation of Donepezil Hydrochloride in patients in Dementia
associated with cerebrovascular disease
- An open-label, multi-center, extended evaluation
of the safety and efficacy of the study medication in patients with
Alzheimer’s disease
- 54-week evaluation of the effects of donepezil hydrochloride on function outcomes in
patients with Alzheimer’s disease with a stage crossover to open-label donpezil hydrochloride treatment
- open-label trial evaluating the safety and
efficacy of donepezil hydrochloride in patients
of Alzheimer’s disease
- A 24-week randomized, double-blind,
placebo-controlled evaluation of the safety and efficacy of donpezil hydrochloride in patients with severe
Alzheimer’s disease followed by a 12 week open label extension period
- A 24-week, multi-center, randomized,
double-blind, placebo-controlled evaluation of the safety and efficacy of donpezil hydrochloride in patients with early
Alzheimer’s disease
- Safety and efficacy of Olanzapine
of cognitive symptoms in subjects with mild to moderate Alzheimer’s
disease
- Safety and efficacy of the Xanolmeline
Transdermal Therapeutic System in patients with
mild to moderate Alzheimer’s disease
- Open label extension of Xanomeline
registration phase efficacy trials using Xanolmeline
Transdermal Therapeutic System
- Fluoxetine versus sertraline and paroxetine in major depression: comparison of
discontinuation-emergent signs and symptoms
- Olanzapine versus risperidone and
placebo in the treatment of Psychosis and Associated Behavioral
Disturbances in patients with dementia
- R-fluoxetine versus
placebo in the treatment of major depression
- the study of Olanzapine
and fluoxetine in combination for treatment
resistant depression without psychotic features
- The efficacy and safety of long term
administration of controlled-release oral Physostigmine
in Alzheimer’s disease and senile dementia of the Alzheimer’s type
- A randomized, double-blind, placebo-controlled
evaluation of the safety and efficacy of memantine
in patients with moderate to severe dementia of the Alzheimer’s type
- A randomized, titration with long-term open-label
evaluation of the safety and efficacy of Memantine
in patients with moderate to severs dementia of the Alzheimer’s type
- A randomized, double-blind, placebo-controlled
evaluation of the safety and efficacy of Mematine
in patients with mild to moderate dementia of the Alzheimer’s type
- Evaluation of a combined regimen of subcutaneous
and oral study medication in the prevention of Migraine recurrence
- A controlled study of Ondansetron
in the treatment of Alzheimer’s type dementia
- A controlled study of Ondansetron
in the treatment of primary degenerative dementia of the Alzheimer’s type
- A double-blind evaluation of the safety and
efficacy of oral ondansetreon in the treatment
of patients with panic disorder
- A long term tolerance and safety study of study
drug in patients with Alzheimer’s disease
- A multi-center, 30 week, double-blind, parallel
group safety, tolerance and efficacy comparison of placebo and Mentane in outpatients with Alzheimer’s disease
- A double-blind placebo controlled, parallel
group, dose range finding study of Lazabemide in
patients with Alzheimer’s disease
- An open label treatment extension study of Lazabemide in patients with Alzheimer’s disease
completing protocol
- Evaluation of the safety and efficacy of fixed
doses of sabeluzone vs. placebo in the treatment
of patients diagnosed with dementia of the Alzheimer’s type
- Clinical evaluation of efficacy and safety of Sabeluzole in the treatment of Alzheimer’s disease
- Efficacy, tolerability and safety of Glalamtamine in the treatment of Alzheimer’s disease
- Long-term safety and efficacy of Glalamtamine in the treatment of Alzheimer’s disease
- Glalamtamine in the treatment of Alzheimer’s disease:
flexible dose range trial
- Safety and efficacy of Glalamtamine
during withdrawal in the treatment of Alzheimer’s disease
- Open-label use of synthetic Glalamtamine
in the treatment of Alzheimer’s disease
- A randomized, placebo-controlled trial to
evaluate the efficacy and safety of Glalamtamine
in patients with minimal cognitive impairment clinically at risk for
development of probable Alzheimer’s disease